Medidata, a leading global provider of cloud-based solutions for clinical research in life sciences, announced on Friday that its clinical cloud platform has been adopted by Walvax Biotechnology Co Ltd, a Yunnan-based biopharmaceutical company, to advance a pediatric vaccine in China.

Walvax is utilizing Medidata's cloud-based technology for electronic data capture and management to drive biomedical innovation. It is also leveraging training through Medidata's professional services, to speed study implementation and ensure trial timelines are met.

Zhang Yi, vice president of Walvax said: "We're pleased to use Medidata's technology to bring greater speed and operational efficiencies to our vaccine trials, ultimately leading to a safe and effective way to ensure young children are protected from the devastating effects of pneumococcal diseases."

"Medidata's cloud-based platform is designed to bring efficiencies to clinical trials of all sizes," said Takeru Yamamoto, Medidata's managing director for the Asia-Pacific region.

He added the cooperation will advance pneumococcal conjugate vaccine research in China, and result in better preventative treatment for young people around the world.

Walvax, founded in 2001, is a modern biological pharmaceutical enterprise engaged in R&D, production and sales of bio-medicine products. It now has a workforce of more than 1,200.

New York-based Medidata, with its cloud-based platform, is transforming the clinical development through its advanced applications and intelligent data analytics. Its clients now include over 90 percent of the top 25 global pharmaceutical companies, innovative biotech and diagnostic and device firms.